ProtoKinetix

ProtoKinetix FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of ProtoKinetix (PKTX) as of Nov 19, 2026 is 48.69 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 77.23 % — a change of -36.95% (lower).

FCF Conversion

48.69 %

YoY

-36.95%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of ProtoKinetix is 2025 48.69 % . FCF Conversion Rate (FCF/EBITDA) of ProtoKinetix was 2024 77.23 % . It decreases by -36.95% lower compared to the previous year.

The ProtoKinetix FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
40.20 USD
Jan 1, 2019
20.86 USD
Jan 1, 2020
12.45 USD
Jan 1, 2021
42.12 USD
Jan 1, 2022
49.12 USD
Jan 1, 2023
104.85 USD
Jan 1, 2024
77.23 USD
Jan 1, 2025
48.69 USD
The ProtoKinetix FCF Conversion history
YEARFCF ConversionYoY
48.69 %-36.95%
77.23 %-26.35%
104.85 %+113.46%
49.12 %+16.63%
42.12 %+238.35%
12.45 %-40.33%
20.86 %-48.11%
40.20 %-8.38%
43.87 %-21.31%
55.75 %+12.66%
49.49 %-63.73%
136.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProtoKinetix stock

FCF Conversion Rate (FCF/EBITDA) of ProtoKinetix is 48.69 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of ProtoKinetix changed from 77.23 % to 48.69 %, representing a -36.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s ProtoKinetix with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ProtoKinetix

All Key Metrics — ProtoKinetix